George Scangos (courtesy Voyager)

George Scan­gos joins Voy­ager board in re­union with Bio­gen col­league Al San­drock

George Scan­gos, a long­time CEO who has helmed a trio of mar­quee names in biotech, is re­turn­ing to the brain and team­ing up with a for­mer Bio­gen col­league.

In his first big move since re­tir­ing as CEO of in­fec­tious dis­ease drug de­vel­op­er Vir Biotech­nol­o­gy last month, Scan­gos is re­unit­ing with Al San­drock at the lat­ter’s Voy­ager Ther­a­peu­tics.

As of to­day, the 75-year-old Scan­gos be­comes a board mem­ber of the biotech, whose pipeline spans the gamut of the brain — Alzheimer’s dis­ease, ALS, Parkin­son’s and oth­er undis­closed cen­tral ner­vous sys­tem dis­eases with gene ther­a­py pro­grams al­lied with Neu­ro­crine, Pfiz­er and No­var­tis.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters